透析療法ネクスト　XII

出版社： 医学図書出版
著者：
発行日： 2011-07-01
分野： 臨床医学：内科  >  腎臓
ISBN： 9784871513890
電子書籍版： 2011-07-01
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,860 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,430 円(税込)

購入する

商品紹介

これを読めば透析患者のかゆみ治療が変わる！

目次

  • 透析療法ネクスト　XII

    ―目次―

    座談会
    『透析そう痒症〜ナルフラフィン塩酸塩への期待と展望〜』

    特集『透析そう痒症の最前線』
    【第1 部　透析そう痒症の原因と治療を知る】
    　かゆみの認知機構　　
    　透析患者のかゆみの疫学　　
    　透析患者のかゆみのメカニズム　
    　かゆみの治療評価　　
    　透析そう痒症治療の現状　
    　透析そう痒症患者のかゆみケア
    【第2 部　選択的κ 作動薬『ナルフラフィン塩酸塩』を知る】
    　新規メカニズムに基づくそう痒症治療薬ナルフラフィン塩酸塩
    　　（レミッチ?カプセル）の創出　
    　ナルフラフィン塩酸塩およびκ受容体作動薬の多彩な薬理作用
    　新しいかゆみ治療薬ナルフラフィン（レミッチ?）の
    　　臨床開発と有効性　
    　ナルフラフィン塩酸塩の長期投与における有効性と安全性　
    　かゆみの実態とナルフラフィン塩酸塩の臨床効果　
    　皮膚症状の変化からみるナルフラフィン塩酸塩の止痒効果　
    　透析療法の歴史（12）―腎性貧血治療の歴史―　　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特集 『透析そう痒症の最前線』

P.18 掲載の参考文献
1) Ikoma A, Steinhoff M, Stander S, et al. : The neurobiology of itch. Nat Rev Neurosci 7 : 535-547, 2006.
PubMed
2) Schmelz M, Schmidt R, Bickel A, et al. : Specific C-receptors for itch in human skin. J Neurosci 17 : 8003-8008, 1997.
PubMed
3) Andrew D, Craig AD : Spinothalamic lamina 1 neurons selectively sensitive to histamine : a central neural pathway for itch. Nat Neurosci 4 : 72-77, 2001.
 
4) Sun YG, Zhao ZQ, Meng XL, et al. : Cellular basis of itch sensation. Science 325 : 1531-1534, 2009.
PubMed
5) Namer B, Carr R, Johanek LM, et al. : Separate peripheral pathways for pruritus in man. J Neurophysiol 100 : 2062-2069, 2008.
 
6) Johanek LM, Meyer RA, Hartke T, et al. : Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 27 : 7490-7497, 2007.
PubMed
7) Ikoma A, Handwerker H, Miyachi Y, et al. : Electrically evoked itch in humans. Pain 113 : 148-154, 2005.
PubMed
8) Drzezga A, Darsow U, Treede R, et al. : Central activation by histamine-induced itch : analogies to pain processing : a correlational analysis of O-15 H (2) O positron emission tomography studies. Pain 92 : 295-305, 2001.
 
9) Mochizuki H, Inui K, Tanabe HC, et al. : Time course of activity in itch-related brain regions : A combined MEG-fMRI study. J Neurophysiol 102 : 2657-2666, 2009.
PubMed
10) Senba E, Katanosaka K, Yajima H, et al. : The immunosuppressant FK506 activates capsaicin-and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 50 : 257-262, 2004.
PubMed
11) McRae CA, Prince MI, Hudson M, et al. : Pain as a complication of use of opiate antagonists for symptom control in cholestasis Gastroenterology 125 : 591-596, 2003.
 
12) Umeuchi H, Togashi Y, Honda T, et al. : Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappaopioid system. Eur J Pharmacol 477 : 29-35, 2003.
PubMed
13) Ikoma A, Rukwied R, Stander S, et al. : Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 139 : 1455-1458, 2003.
PubMed
14) Ikoma A, Fartasch M, Heyer G, et al. : Painful stimuli evoke itch in patients with chronic pruritus : Central sensitization for itch. Neurology 62 : 212-217, 2004.
PubMed
15) Sugiura T, Tominaga M, Katsuya H, et al. : Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 88 : 544-548, 2002,
PubMed
16) Vergnolle N, Bunnett NW, Sharkey KA, et al. : Proteinase-activated receptor-2 and hyperalgesia : A novel pain pathway Nat Med 7 : 821-826, 2001.
PubMed
17) Yamaguchi J, Nakamura F, Aihara M, et al. : Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J Invest Dermatol 128 : 2842-2849, 2008.
 
18) Woolf CJ, Salter MW : Neuronal plasticity : increasing the gain in pain Science 288 : 1765-1769, 2000.
PubMed
19) Schmelz M, Hilliges M, Schmidt R, et al. : Active "itch fibers" in chronic pruritus. Neurology 26 ; 61 : 564-566, 2003.
 
P.32 掲載の参考文献
1) Pisoni RL, Wikstrom B, Elder SJ, et al. : Pruritus in hemodialysis patients : International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transpant 21 : 3495-3505, 2006.
 
2) Schwartz IF, Iaina A : Uremic pruitus. Nephrol Dial Transplant 14 : 834-839, 1999.
 
3) Robinson-Bostom L, DiGiovanna JJ : Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 43 : 987-990, 2000.
 
4) Lin HH, Liu YL, Liu JH, et al. : Uremic pururitus, cytokines, and polymethylmethacrylate artificial kidney. Artificial Organs : 32 : 468-472, 2008.
 
5) 大森健太郎, 青池郁夫, 青柳春樹, 他 : 透析皮膚掻痒症の実態-新潟県内41施設2474名の調査報告-. 透析会誌 34 : 1469-1477, 2001.
 
6) Narita I, Aichi B, Omori K, et al. : Etiology and prognostic siginificance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69 : 1626-1632, 2006.
 
7) Mathur SV, Lindberg J, Germain M, et al. : A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Nephrol 5 : 1410-1419, 2010.
 
8) Cho YL, Liu HN, Huang TP, et al. : Uremic pruritus : Role of parathyroid hormone and substance P. J Am Acad Dermatol 36 : 538-543, 1997.
PubMed
9) Kuypers DR, Claes K, Evenepoel P, et al. : A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 19 : 1895-1901, 2004.
 
10) Duque MI, Yosipovitch G, Fleischer AB Jr, et al. : Lack of efficacy of tacrolimus ointment 011% for treatment of hemodialysis-related pruritus : a randomized, douvle-blind, vehicle-controlled study. J Am Acad Dermatol 52 : 519-521, 2005.
 
11) US Food and Drug Administration (online 10 March 2005) FDA Public Health Advisory : Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. [www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Elidel］
 
12) Charlesworth EN, Beltrani VS : Pruritic dermatoses : overview of etiology and therapy. Am J Med 113 : 25S-33S, 2002.
PubMed
13) Gilchrest BA, Rowe JW, Brown RS, et al. : Ultraviolet phototherapy of uremic pruritus. Lonf-term results and possible mechanism of action. Ann Intern Med : 91 : 17-21, 1979.
 
14) Cohen EP, Russell TJ, Garancis JC : Mast cells and calcium in severe uremic itching. Am J Med Sci 303 : 360-365, 1992.
PubMed
15) Wikstrom B, Gellert R, Ladefoged SD, et al. : Kappa-opioid system in uremic pruritus : multicenter, randomized, double-blind, placebo-controled clinical studies. J Am Soc Nephrol 16 : 3742-3747, 2005.
 
16) Hiroshige K, Kabashima N, Takasugi M, et al. : Optimal dialysis improves uremic pruritus. Am J Kid Dls 24 : 413-419, 1995.
 
17) De Marchi S, Cecchin E, Villalta D, et al. : Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 326 : 969-974, 1992.
PubMed
18) Balaskas EV, Uldall RP : Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int 12 : 330-331, 1992.
 
19) Massry SG, Popovtzer MM, Coburn JW, et al. : Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disapperance of itching after subtotal parathyroidectomy. N Engl J Med 279 : 697-700, 1968.
 
20) Carmichael AJ, McHugh M, Martin AM, et al. : Serological markers of renal itch in patients receiving long-term haemodialysis. Br Med J 296 : 1575, 1988.
 
21) Ostlere LS, Taylor C, Baillod R, et al. : Relationship between pruritus, transepidermal water loss, and biochemical markers of renal itch in haemodialysis patients. Nephrol Dial Transplant 9 : 1302-1304, 1994.
PubMed
22) Johansson O, Hilliges M, Stahle-Backdahl M : Intraepidermal neuron-specific enolase (NSE) -immunnoreactive nerve fibres ; evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 99 : 281-286, 1989.
 
P.39 掲載の参考文献
1) Greaves MW : Pruritus. Rook's Textbook of Dermatology. Ed. Burns T., Breathnach S., Cox N., Griffith C.. Vol. 1, Seventh Edition, Blackwell Science, pp16.1-17.7.
 
2) Shelley WB, Arthur RP : The neurohistology and neurophysiology of the itch sensation in man. Arch. Dermatol 76 : 296-323, 1957.
 
3) Tuckett RP : Neurophysiology and neuroanatomy of pruritus Itch-Mechanisms and Management of Pruritus. Ed. J. D. Bernhard. McGraw-Hill, Inc, pp 1-22, 1994.
 
4) Shelley WB, Arthur RP : Studies on cowhage (mucana pruriens) and its pruritogenic proteinase, mucunain. Arch. Dermatol 72 : 399-406, 1955.
 
5) Schmelz M : Itch-mediators and mechanisms. J Dermato Sci 28 : 91-96, 2002.
 
6) Schmelz M, Schmidt R, Bickel A : Specific Creceptors for itch in human skin. J Neurosci 17 : 8003-8008, 1997.
PubMed
7) Sun YG, Chen ZF : Agastrun-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448 : 700-703, 2007.
PubMed
8) Tominaga M, Ogawa H, Takamori K : Histological Characterization of Cutaneous Nerve fibers Containing Gastrin-Releasing Peptide in NC/Nga Mice : An Atopic Dermatitis Model. J Invest Dermatol 129 : 2901-2915, 2009.
 
9) Johansson O, Hilliges M, Stahle-Backdahl M : Intraepidermal neuron-specific enolase (NSE) immunoreactive nerve fibers : evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 99 : 281-286, 1989.
PubMed
10) Bernstein J, Swift R, Soltani K : Antipruritic effect on an opiate antagonist, naloxon hydrochloride. J Invest Dermatol 78 : 82-83, 1982.
 
11) Pan ZZ : μ-opposing actions of the κ-opioid receptor. Trends Pharmacol Sci 19 : 94-98, 1998.
 
12) 服部瑛 : 透析患者と皮膚病変. 北関東医学 37 : 539-547, 1987.
 
13) 大森健太郎, 成田一衛, 下条文武 : 透析皮膚掻痒症の実態-新潟県内41施設2474名の調査報告-, 透析会誌 34 : 1469-1477, 2001.
 
14) Takamori K, Takimoto R, Hase T : Mechanisms of itch in dry skin-NGF induces the elongation/penetration of nerve fibers into the epidermis. Confernce Handbook in International Workshop for the Study of Itch., Singapore, P36, 2001.
 
15) Tominaga M, Ozawa S, Tengara S, et al : Intraepidermal nerve fibers increase in dry skin of acetone-treated rnice. J Dermatol Sci 48 : 103-111, 2007.
PubMed
16) Tominaga M, Ozawa S, Ogawa H, et al : A hypothetical mechanisrn of intraepidermal neurite formation on NC/Nga mice with atopic dermatitis. J Dermatol Sci 46 : 199-210, 2007.
 
17) Johansson O, Hilliges M, Stahle-Backdahl M : Intraepidermal neurone specific enolase (NSE) -immunoreactive nerve fibers : evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 99 : 281-286, 1989.
PubMed
18) Tominaga M, Ogawa H, Takamori K : Decreased production of semaphoring 3A in the lesional skin of atopic dermatitis. Br J Dermatol 158 : 842-844, 2008.
 
19) Tominaga M, Takamori K : Recent advances in pathophysiological mechanisms of itch. Expert Review 5 : 197-212, 2010.
 
20) Kumagai H, Utsumi J, Saruta T, et al : Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. Itch-basic mechanisms and therapy, New York, pp279-286, 2004.
 
21) Togashi Y, Umeuchi K, Okano K, et al : Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435 : 259-264, 2002.
 
22) Kumagai H, Ebata T, Takamori K, et al : Effect of a novel kappa-receptor agonist, narufurafn hydrochloride, on severe itch in 337' haemodialysis patients ; a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2010.
PubMed
P.48 掲載の参考文献
1) Narita I, Alchi B, Omori K, et al : Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69 : 1626-1632, 2006.
PubMed
2) 江畑俊哉 : 透析患者の皮膚癌痒 治療戦略総論. 皮膚科の臨床 52 : 1737-1742, 2010.
 
3) 江畑俊哉 : ヒトにおけるかゆみの評価. 医学のあゆみ 197 : 581-585, 2001.
Medical*Online
4) 江畑俊哉 : 痒みを定量化する. Visual Dermatology 2 : 952-956, 2003.
 
5) 山田秀和, 野田剛弘, 松倉正治, 他 : VAS法 (Visual Analogue Scale) を用いた痒みの評価法について. 皮膚 38 (増18) : 71-77, 1996.
 
6) Kumagai H, Ebata T, Takamori K, et al : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomised, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2010.
PubMed
7) 江畑俊哉, 泉裕乃, 相澤浩, 他 : 痒みの臨床的評価法について-Symtrackの使用経験とVisual analogue scale法, Numerical rating scale法との比較-. 日皮アレルギー 6 : 89-95, 1998.
Medical*Online
8) 川島眞, 原田昭太郎, 丹後俊郎 : 掻痒の程度の新しい判定基準を用いた患者日誌の使用経験. 臨皮 56 : 692-697, 2002.
 
9) 生駒晃彦 : 痒み過敏～その実例と治療. Visual Dermatology 6 : 696-697, 2007.
 
10) Ebata T, Aizawa H, Kamide R : An infrared video camera system to observe nocturnal scratching in atopic dermatitis patients, J Dermatol 23 : 153-155, 1996.
PubMed
11) Ebata T, Aizawa H, Kamide R, et al : The characteristics of nocturnal scratching in adults with atopic dermatitis. Br J Dermatol 141 : 82-86, 1999.
PubMed
12) Ebata T, Iwasaki s, Aizawa H, et al : Use of a wrist activity monitor for the measurement of nocturnal scratching in patients with atopic dermatitis. Br J Dermatol 144 : 305-309, 2001.
 
P.54 掲載の参考文献
1) Hiroshige K Kabashima N, Takasugi M, et al. : Optimal dialysis improves uremic pruritus. Am J Kidney Dis 25 : 413-419, 1995.
PubMed
2) Kato A, Takita T, Furuhashi M, et al. : Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients : crossover study and role of tumor necrosis factor-alpha. Artif Organs 25 : 441-447, 2001.
PubMed
3) Lin HH, Liu YL, Liu JH, et al. : Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs 32 : 468-472, 2008.
PubMed
4) Mistik S, Utas S, Ferahbas A, et al. : An epidemiology study of patients with uremic pruritus. J Eur Acad Dermatol Venereol 20 : 672-678, 2006.
PubMed
5) Kyriazis J, Glotsos J. : Dialysate calcium concentration of </=1.25 mmol/l : is it effective in suppressing uremic pruritus? Nephron 84 : 85-86, 2000.
 
6) Robertson KE, Mueller BA. : Uremic pruritus. Am J Health Syst Pharm 53 : 2159-2170 ; quiz 2215-2216, 1996.
 
7) Subach RA, Marx MA. : Evaluation of uremic pruritus at an outpatient hemodialysis unit. Ren Fai 124 : 609-614, 2002.
 
8) Akhyani M, Ganji MR, Samadi N, et al. : Pruritus in hemodialysis patients. BMC Derrnatol 5 : 7, 2005.
PubMed
9) Leong SO, Tan CC, Lye WC, et al. : Dermal mast cell density and pruritus in end-stage renal failure. Ann Acad Med Singapore 23 : 327-329, 1994.
PubMed
10) Morton CA, Lafferty M, Hau C, et al. : Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 11 : 2031-2036, 1996.
PubMed
11) Szepietowski JC, Reich A, Szepietowski T. : Emollients with endocannabinoids in the treatment of uremic pruritus : discussion of the therapeutic options. Ther Apher Dial 9 : 277-279, 2005.
PubMed
12) Okada K, Matsumoto K. : Effect of skin care with an emollient containing a high water content on mild uremic pruritus. Ther Apher Dial 8 : 419-422, 2004.
PubMed
13) Weisshaar E, Dunker N, Gollnick H. : Topical capsaicin therapy in humans with hemodialysis-related pruritus. Neurosci Lett 345 : 192-194, 2003.
PubMed
14) Fivenson DP, Breneman DL, Rosen GB, et al. : Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130 : 753-758, 1994.
PubMed
15) Tarng DC, Cho YL, Liu HN, et al. : Hemodialysis-related pruritus : adouble-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 72 : 617-622, 1996.
 
16) Pauli-Magnus C, Klumpp S, Alscher DM, et al. : Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 20 : 802-803, 2000.
PubMed
17) Kuypers DR, Claes K, Evenepoel P, et al. : A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 19 : 1895-1901, 2004.
 
18) Chen YC, Chiu WT, Wu MS. : Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 48 : 69-76, 2006.
PubMed
19) Gilchrest BA, Rowe JW, Brown RS, et al. : Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 91 : 17-21, 1979.
PubMed
20) Seckin D, Demircay Z, Akin O. : Generalized pruritus treated with narrowband UVB. Int J Dermatol 46 : 367-370, 2007.
PubMed
21) Che-Yi C, Wen CY, Min-Tsung K, et al. : Acupuncture in haemodialysis patients at the Quchi (LI11) acupoint for refractory uraemic pruritus. Nephrol Dial Transplant 20 : 1912-1915, 2005.
PubMed
22) Gao H, Zhang W, Wang Y : Acupuncture treatment for 34 cases of uremic cutaneous pruritus. J Tradit Chin Med 22 : 29-30, 2002.
 
P.63 掲載の参考文献
1) 段野貴一郎 : 透析室に置きたいかゆみ治療パーフェクトガイド, 金芳堂, 京都, p4-6, 2008.
 
2) 高森建二 : 皮膚疾患の病態, ドライスキンによるかゆみのメカニズム, 臨床皮膚 54 : 52-56, 2000.
 
3) 熊谷裕生, 他 : 透析治療における新しい薬物. 透析患者のかゆみに対するκ-アゴニスト. 臨床透析 22 : 763-772, 2006.
 
4) 段野貴一郎 : ここがツボ患者に伝える皮膚外用剤の使い方, 金芳堂, 京都, 2009.
 
5) 高森建二 : オピオイドペプチドを標的としたかゆみの治療, 臨床皮膚 56 : 145-147, 2002.
 
P.75 掲載の参考文献
1) 長瀬博, 山本尚 : 創薬「薬物分子設計のコツ」, エルゼビアサイエンス株式会社, ミクス, 241-272, 2001.
 
2) Lahti RA, Von Voigtlander PF, Barsuhn C : Properties of a selective kappa agonist, U-50, 488H. Life Sci 31 : 2257-2260, 1982.
PubMed
3) Casy AF, Parfitt RT : Opioid Analgesics, Plenum Press, N. Y., 1986.
 
4) Lipkowski AW, Tam SW, Portoghese PS : Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem 29 : 1222-1225, 1986.
PubMed
5) a) Portoghese PS, Lipkowski AW, Takemori AE : Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40 : 1287-1292, 1987. b) Portoghese PS, Sultana M, Nagase H, et al. : Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem 31 : 281-282, 1988. c) Portoghese PS, Sultana M, Takemori AE : Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J pharmacol 146 : 185-186, 1988. d) Portoghese PS, Nagase H, Lipkowski AW, et al. : Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem 31 : 836-841, 1988.
 
6) Nagase H, Hayakawa J, Kawamura K, et al. : Discovery of a structurally novel opioid kappa-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull 46 : 366-369, 1998.
PubMed
7) Kawai K, Hayakawa J, Nagase H, et al. : Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists. Bioorg Med Chem 16 : 9188-9201, 2008.
PubMed
8) Seki T, Awamura S, Nagase H, et al. : Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J pharmacol 376 : 159-167, 1999.
PubMed
9) Wang Y, Tang K, Cowan A, et al. : Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J pharmacol Exp Ther 312 : 220-230, 2005.
 
10) Nagase H, et al. : unpublished result.
 
11) 長瀬博, 遠藤孝, 田中利明 : オピオイドの基礎と臨床 (鎮痛薬・オピオイドペプチド研究会編), ミクス 144-154, 2000.
 
12) Takasaki I, Suzuki T, Sasaki A, et al. : Suppression of acute herpetic pain related responses by the kappa-opioid receptor agonist (-) -17-cyclopropylmethyl-3, 14betadihydroxy-4, 5alpha-epoxy-6beta- [N-methyl-3-trans-3- (3-furyl) acrylamido］morphinan hydrochloride (TRK-820) in mice. J pharm acol Exp Ther 309 : 36-41, 2004.
 
13) 中尾薫, 安藤晃裕, 平形美樹人, 他 : 新規経口そう痒症改善薬ナルフラフィン塩酸塩 (レミッチカプセル2.5μg) の特徴及び臨床試験成績. 日本薬理学雑誌 135 : 205-214, 2010.
 
14) Kuraishi Y, Nagasawa T, Hayashi K, et al. : Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 275 : 229-233, 1995.
 
15) Togashi Y, Umeuchi H, Nagase H, et al. : Antipruritic activity of the k-opioid receptor agonist, TRK-820. Eur J pharmacol 435 : 259-267, 2002.
 
16) 長瀬博, 富樫裕子 : 鎮痛・オピオイド研究最前線 (鎮痛薬・オピオイドペプチド研究会), エルゼビア・サイエンス株式会社, ミクス, 62-69, 2002.
 
17) Wakasa Y, Fujiwara A, Nagase H, et al. : Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75 : 2947-2957, 2004.
PubMed
P.90 掲載の参考文献
1) 中尾薫, 長谷部光, 吉川悟, 他 : オピオイドκ受容体作動薬ナルフラフィン塩酸塩の薬理作用 日神精薬理誌 30 : 185-191, 2010.
 
2) Togashi Y, Umeuchi H, Okano K, et al. : Antipruritic activity of theκ-opioid receptor agonist, TRK-820. Eur J pharmacol 435 : 259-264, 2002.
 
3) Tohda C, Yamaguchi T, Kuraishi Y : Intracisternal injection of opioids induces itch-associated response through μ-opioid receptors in mice, Jpn J Pharmacol 74 : 77-82, 1997.
 
4) Umeuchi H, Togashi Y, Honda T, et al. : Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system. Eur J pharmacol 477 : 29-35, 2003.
 
5) Wakasa Y, Fujiwara A, Umeuchi H, et al. : Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75 : 2947-2957, 2004.
PubMed
6) Ko MC, Husbands SM : Effects of atypical κ-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328 : 193-200, 2009.
 
7) Kaku H, Fujita Y, Yago H, et al. : Study on pruritus in hemodialysis patients and the antipruritic effect of Neurotropin : Plasma levels of substance P, somatostatin, IgE, PTH and histamine. Jpn J Nephrol 32 : 319-326, 1990.
 
8) Tarng DC, Cho YL, Liu HN, et al. : Hemodialysis-related pruritus : adouble-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 72 : 617-622, 1996.
 
9) Thornton JR, Losowsky MS : Plasma β endorphin in cirrhosis and renal failure. Gut 32 : 306-308, 1991.
 
10) 熊谷裕生, 林松彦, 猿田享男 : 維持血液透析患者のかゆみにおける内因性オピオイドの関与. 臨床薬理 31 : 457-458, 2000.
 
11) 高森建二 : 透析患者の痒みの機序とオピオイドペプチド. Visual Dermatology 3 : 534-537, 2004.
 
12) Danno K, Nishiura K, Tanaka M : Increased met-enkephalin plasma levels in hemodialysis patients with or without pruritus. J Dermatol Sci 10 : 238-240, 1995.
PubMed
13) Peer G, Kivity S, Agami O, et al. : Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348 : 1552-1554, 1996.
PubMed
14) Pauli-Magnus C, Mikus G, Alscher DM, et al. : Naltrexone does not relieve uremic pruritus : results of a randomized, doubleblind, placebo-controlled crossover study. J Am Soc Nephrol 11 : 514-519, 2000.
 
15) Kumagai H, Ebata T, Takamori K, et al. : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2010.
PubMed
16) 中尾薫, 安藤晃裕, 平形美樹人, 他 : 新規経口そう痒症改善薬ナルフラフィン塩酸塩 (レミッチ(R) カプセル2.5μg) の特徴および臨床試験成績. 日薬理誌 135 : 205-214, 2010.
Medical*Online
17) Wikstr6m B, Gellert R, Ladefoged SD, et al. : κ-opioid system in uremic pruritus : multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16 : 3742-3747, 2005.
 
18) Nakao K, Mochizuki H : Nalfurafine hydrochloride : a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today 45 : 323-329, 2009.
PubMed
19) Inan S, Cowan A : Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 85 : 39-43, 2006.
PubMed
20) Umeuchi H, Kawashima Y, Aoki CA, et al. : Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 518 : 133-139, 2005.
 
21) 中尾薫, 池田顕, 黒川敬弘, 他 : アトピー性皮膚炎モデルの引っ掻き行動に対するオピオイドκ受容体作動薬TRK-820の効果. 日神精薬理誌 28 : 75-83, 2008.
 
22) Inan S, Cowan A : Kappa opioid agonists suppress chloroquine-induced scratching in mice. Eur J Pharmacol 502 : 233-237, 2004.
PubMed
23) Nagase H, Hayakawa J, Kawamura K, et al. : Discovery of a structurally novel opioid κ-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull 46 : 366-369, 1998.
 
24) Endoh T, Matsuura H, Tajima A, et al. : Potent antinociceptive effects of TRK-820, a novel κ-opioid receptor agonist. Life Sci 65 : 1685-1694, 1999.
 
25) Endoh T, Tajima A, Suzuki T, et al. : Characterization of the antinociceptive effects of TRK-820 in the rat. Eur J pharmacol 387 : 133-140, 2000.
PubMed
26) Endoh T, Tajima A, Izumimoto N, et al. : TRK-820, a selective κ-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn J Pharmacol 85 : 282-290, 2001.
 
27) Takasaki I, Suzuki T, Sasaki A, et al. : Suppression of acute herpetic pain-related responses by the κ-opioid receptor agonist (-) -17-cyclopropylmethyl-3, 14β-dihydroxy-4, 5α-epoxy-6β- [N-methyl-3一trans-3- (3-furyl) acrylamido］morphinan hydrochloride (TRK-820) in mice. J Pharmacol Exp Ther 309 : 36-41, 2004.
 
28) IASP Taxonomy Working Group : Pain Terms, Changes in the 2011 list, IASP Taxonomy, in "http://www.iasp-pain.org/AM/Template.cfm?Section=Pain_Defi...isplay.cfm&ContentID=1728"
 
29) Ohsawa M, Kamei J : Modification of κ-opioid receptor agonist-induced antinociception by diabetes in the mouse brain and spinal cord. J Pharmacol Sci 98 : 25-32, 2005.
 
30) Yoshida C, Nakao K, Mochizuki H : Effects of TRK-820, a selective κ-opioid receptor agonist, on mechanical allodynia in partial sciatic nerve ligated rats or streptozotocin-induced diabetic rats. J Pharmacol Sci 109 (Suppl 1) : 223p, 2009.
 
31) Takasaki I, Nojima H, Shiraki K, et al. : Specific down-regulation of spinal μ-opioid receptor and reduced analgesic effects of morphine in mice with postherpetic pain. Eur J Pharmacol 550 : 62-67, 2006.
 
32) Yoshikawa S, Hareyama N, Ikeda K, et al. : Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models. Eur J Pharmacol 606 : 102-108, 2009.
PubMed
33) Ikeda K, Yoshikawa S, Kurokawa T, et al. : TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of parkinson's disease. Eur J Pharmacol 620 : 42-48, 2009.
 
34) Tsuji M, Takeda H, Matsumiya T, et al. : A novel κ-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci 66 : PL353-358, 2000.
 
35) Tsuji M, Takeda H, Matsumiya T, et al. : The novel κ-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci 68 : 1717-1725, 2001.
 
36) Mori T, Nomura M, Nagase H, et al. : Effects of a newly synthesized κ-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology 161 : 17-22, 2002.
 
37) Ise Y, Narita M, Nagase H, et al. : Modulation of κ-opioidergic systems on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Neurosci Lett 323 : 164-166, 2002.
 
38) Hasebe K, Kawai K, Suzuki T, et al. : Possible pharmacotherapy of the opioid κ receptor agonist for drug dependence. In, Current Status of Drug Dependence/Abuse Studies : Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity (Annals of the New York Academy of Sciences, vol. 1025). Wiley-Blackwell, New Jersey, pp 404-413, 2004.
 
39) Kao TK, Ou YC, Liao SL, et al. : Opioids modulate post-ischemic progression in a rat model of stroke. Neurochem Int 52 : 1256-1265, 2008.
 
40) Charron C, Messier C, Plamondon H : Neuroprotection and functional recovery conferred by administration of kappa-and delta1-opioid agonists in a rat model of global ischemia. Physiol Behav 93 : 502-511, 2008.
 
41) Ukai M, Kobayashi T, Kameyama T : Dynorphin A- (1-13) attenuates basal forebrainlesion-induced amnesia in rats. Brain Res 625 : 355-356, 1993.
 
42) 鵜飼良 : 内在性オピオイドペプチドによるアルツハイマー型老人性痴呆治療薬の開発研究. 持田記念財団・研究成果報告集 10 : 152-156, 1994.
 
43) Hiramatsu M, Hyodo T, Kameyama T : U-50488H, a selective κ-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice. Eur J pharmacol 315 : 119-125, 1996.
 
44) Hiramatsu M, Hyodo T, Kameyama T : U-50,488H, a selective kappa opioid receptor agonist, ameliorates memory impairments induced by muscarinic autoreceptor agonist, carbachol in mice. Neurosci Lett 236 : 45-48, 1997.
PubMed
45) Hiramatsu M, Murasawa H, Nabeshima T, et al. : Effects of U-50,488H on scopolamine-, mecamylamine-and dizocilpine-induced learning and memory impairment in rats. J Pharmacol Exp Ther 284 : 858-867, 1998.
PubMed
46) Hiramatsu M, Kameyama T : Roles of κ-opioid receptor agonists in learning and memory impairment in animal models. Meth Find Exp Clin Pharmacol 20 : 595-599, 1998.
 
47) 鵜飼良 : 鎮痛作用以外の薬理作用-学習・記憶-, 特集 オピオイドをめぐる最近の話題. ペインクリニック 23 : 945-951, 2002.
 
48) Rong F, Peng Z, Ming-Xiang Y, et al. : Myocardial apoptosis and infarction after ischemia/reperfusion are attenuated by κ-opioid receptor agonist. Arch Med Res 40 : 227-234, 2009.
 
49) Tong G, Sun Z, Wei X, et al. : U50,488H postconditioning reduces apoptosis after myocardial ischemia and reperfusion. Life Sci 88 : 31-38, 2011.
PubMed
50) Burton MB, Gebhart GF : Effects of kappaopioid receptor agonists on responses to colorectal distension in rats with and without acute colonic infiammation. J Pharmacol Exp Ther 285 : 707-715, 1998.
 
51) Mangel AW, Bornstein JD, Hamm LR, et al. : Clinical trial : asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 28 : 239-249, 2008.
PubMed
52) Talley NJ, Choung RS, Camilleri M, et al. : Asimadoline, a kappa-opioid agonist, and satiation in functional dyspepsia. Aliment Pharmacol Ther 27 : 1122-1131, 2008.
PubMed
P.107 掲載の参考文献
1) Schwartz IF, Iaina A : Uraemic pruritus. Nephrol Dialysis Transplant 14 : 834-839, 1999.
 
2) Yosipovitch G, Greaves MW, Schmelz M : Itch. Lancet 361 : 690-694, 2003.
PubMed
3) Mettang T, Pauli-Magnus U, Alscher DM : Uraemic pruritus-new perspectives and insights from recent trials. Nephrol Dial Transplant 17 : 1558-1563, 2002.
 
4) Ikoma A, Steinhoff M, Schmelz M, et al. : The neurobiology of itch. Nature Rev Neurosci 7 : 535-547, 2006.
 
5) Pisoni R, Wikstrom B, Akizawa T, et al. : Pruritus in haemodialysis patients : international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 21 : 3495-3505, 2006.
PubMed
6) 大森健太郎, 成田一衛, 下条文武, 他 : 透析皮膚掻痒症の実態-新潟県内41施設2474名の調査報告- 日本透析会誌 34 : 1469-1477, 2001.
 
7) Narita I, Omori K, Gejyo F, et al. : Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69 : 1626-1632, 2006.
PubMed
8) Kumagai H, Ebata T, Suzuki H, et al. : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomised, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation 25 : 1251-1257, 2010.
 
9) Kumagai H, Utsumi J, Saruta T, et al. : Prospects for a novel κ-opioid receptor agonist, TRK-820, in uremic pruritus. In "Itch. Basic Mechanisms and Therapy" ed by Yosipovitch G. Marcel Dekker, New York, pp279-286, 2004.
 
10) 熊谷裕生, 丸山資郎, 高森建二, 他 : 「透析患者のかゆみに対するκ-アゴニストTRK-820. 透析治療における新しい薬物」臨床透析 22 : 763-772, 2006.
 
11) Peer G, Kivity S, Aqami O, et al. : Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 348 : 1552-1554, 1996.
 
12) Pauli-Magus C, Mikus T, Mettang T, et al. : Naltrexone does not relieve uremic pruritus : results of a randomized, placebo-conrolled crossover-study. J Am Soc Nephrol 11 : 514-519, 2000.
 
13) Pan ZZ : μ-opposing actions of the κ-opioid receptor. Trend in Pharmacol Sci 19 : 94-98, 1998.
 
14) Margolis EB, Hjelmstad GO, Bonci A, et al. : κ-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23 : 9981-9986, 2003.
 
15) 鈴木知比古, 内海潤, 熊谷裕生, 他 : RTPCRによるヒト末梢血リンパ球のオピオイド受容体およびノシセプチン受容体の発現解析. 臨床薬理 31 : 455-456, 2000.
 
16) Togashi Y, Umeuchi K, Nagase H, et al. : Antipruric activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 435 : 259-264, 2002.
 
17) Seki T, Awamura S, Kimura C, et al. : Pharmacological properties of TRK-820 on cloned mu-, delta-and kappa-opioid receptors and nociceptin receptor. Eur J pharmacol 376 : 159-167, 1999.
PubMed
18) Nagase H, Hayakawa J, Kawamura K, et al. : Discovery of a structurally novel opioid kappa-agonist derived from 4, 5-epoxymorphinan. Chem Pharm Bull 46 : 366-369, 1998.
PubMed
19) Wakasa Y, Fujiwara A, Nagase H, et al. : Inhibitory effects of TRK-8200n systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 75 : 2947-2957, 2004.
 
20) Umeuchi H, Togashi Y, Nagase H, et al. : Involvement of central μ-opioid system in the scratching behavior in mice, and the suporession of it by the activation of κ-opioid system. Eur J Pharmacol 477 : 29-35, 2003.
 
21) Kamei J, Nagase H : Norbinaltorphimine, a selective κ-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 418 : 141-145, 2001.
 
22) Bigliardi PL, Bigliardi-Qi M, Buechner S, et al. : Expression of m-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 111 : 297-301, 1998.
 
23) Bigliardi PL, Strammer H, Jost G, et al. : Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 56 : 979-988, 2007.
 
24) Tominaga M, Ogawa H, Takamori K : Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 127 : 2228-2235, 2007.
PubMed
25) 熊谷裕生, 江畑俊哉, 鈴木洋通, 他 : 血液透析患者のかゆみに対する, カッパ受容体作動薬ナルフラフィンの有効性. 日本透析医会雑誌 24 : 387-395, 2009.
 
26) 栗原雅直, 他 : 二重盲検法によるID-540 (Fludiazepam), DiazepamおよびPlaceboの神経症による薬効の比較ならびに依存性調査表試案について. 臨床評価 5 : 341-368, 1977.
 
P.117 掲載の参考文献
1) 鈴木洋通 : 慢性腎臓病関連皮膚掻痒症. 臨床透析 25 : 918-925, 2009.
 
2) Narita I, Alchi B, Omori K, et al. : Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 69 : 1626-1632, 2006.
PubMed
3) Peterson RA, Kimmel PL, Sacks CR, et al. : Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 21 : 343-354, 1991.
PubMed
4) Kimmel PL, Peterson RA, Weihs KL, et al. : Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 57 : 2093-2098, 2000.
 
5) Pisoni RL, Wikstrom B, Elder SJ, et al. : Pruritus in haemodialysis patients : international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant 21 : 3495-3505, 2006.
PubMed
6) 松橋満弥, 川上美和, 近藤みか, 他 : 経口掻痒改善剤ナルフラフィン塩酸塩 (レミッチめの使用経験. 秋田腎不全研究会誌 13 : 98-102, 2010.
 
7) 佐武喜美子, 桝屋根佳子, 中川典子, 他 : 経口掻痒症改善薬レミッチの当院における長期投与試験の結果について. 大阪透析研究会会誌 27 : 163-167, 2009.
Medical*Online
8) Kumagai H, Ebata T, Takamori K, et al. : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomized, double-blind, placebo-controlled study. Nephrol. Dial. Transplant 25 : 1251-1257, 2010.
PubMed
9) 熊谷裕生, 江畑俊哉, 鈴木洋通, 他 : 血液透析患者のかゆみに対する, カッパ受容体作動薬ナルフラフィンの有効性. 日本透析医学会雑誌 24 : 387-395, 2009.
 
10) 熊谷裕生, 丸山資郎, 江畑俊哉, 他 : 血液透析患者の痒みに対する, κ受容体作動薬ナルフラフィンの効果アレルギー. 免疫 17 : 1520-1529, 2010.
 
11) 吉澤拓, 弓取知子, 中島志保, 他 : 血液透析患者の治療抵抗性掻痒症に対するκ受容体作動薬ナルフラフィン塩酸塩 (レミッチ(R)) の治療効果について. 中国腎不全研究会誌 18 : 237-238, 2009.
 
12) 大森健太郎, 青池郁夫, 青柳春樹, 他 : 透析皮膚掻痒症の実態. 日本透析医学会雑誌 34 : 1469-1477, 2001.
 
13) 段野貴一郎 : 透析の痒み治療最前線Visual Dematology 3 : 526-533, 2004.
 
14) Schwartz IF, Iaina A : Uraemic pruritus (review). Nephrol Dial Transplant 14 : 834-839, 1999.
PubMed
15) 中井滋, 新里高広, 佐中孜, 他 : わが国の慢性透析療法の現況 (1999年12月31日現在). 日本透析医学会雑誌 34 : 1-31, 2001.
 
16) 弓取知子, 吉澤拓, 中島志保, 他 : 当院における血液透析患者の皮膚掻痒症の実態について. 中国腎不全研究会誌 18 : 235-236, 2009.
 
17) 小名慎二, 他 (東レ株式会社) : 血液透析患者におけるそう痒症に対する効果の検討 (長期投与試験社内資料)
 
P.125 掲載の参考文献
1) Mettang T, Pauli-Magnus C, Alscher DM : Uraemic pruritus-new perspectives and insights from recent trials. Nephrol Dial Transplant 17 : 1558-1563, 2002.
PubMed
2) Merkus MP, Jager KJ, Dekker FW, et al. : Physical symptoms and quality of life in patients on chronic dialysis : results of The Netherlands Cooperative Study on Adequacy of Dialysls (NECOSAD). Nephrol Dial Transplant 14 : 1163-1170, 1999.
 
3) Mettang T, Weisshaar E. Pruritus : control of itch in patients undergoing dialysis. Skin Therapy Lett 15 : 4-5, 2010.
 
4) Yosipovitch G, Zucker I, Boner G, et al. : A questionnaire for the assessment of pruritus : validation in uremic patients. Acta Derm Venereol 81 : 108-111, 2001.
PubMed
5) Curtin RB, Bultman DC, Thomas-Hawkins C, et al. : Hemodialysis patients'symptom experiences : effects on physical and mental functioning. Nephrol Nursing J 29 : 562-574, 2002.
PubMed
6) Biro T, Ko MC, Bromm B, et al. : How best to fight that nasty itch-from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 14 : 225-240, 2005.
PubMed
7) Pisoni RL, Wikstr6m B, Elder SJ, et al. : Pruritus in haemodialysis patients : International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 12 : 3495-3505, 2006.
 
8) Gilchrest BA, Rowe JW, Brown RS, et al. : Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanisms of action. Ann Intern Med 91 : 17-21, 1979.
PubMed
9) Tarng DC, Cho YL, Liu HN, et al. : Hemodialysis-related pruritus : a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 72 : 617-622, 1996.
 
10) Weisshaar E, Dunker N, Gollnick H : Topical capsaicin therapy in humans with hemodialysis-related pruritus. NeurosciLett 345 : 192-194, 2003.
 
11) Kyriazis J, Glotsos J : Dialysate calcium concentration of <1.25 mmol/l : is it effective in supPressing uremic pruritus? Nephron 84 : 85-86, 2000.
 
12) Pauli-Magnus C, Mikus G, Alscher DM, et al. : Naltrexone does not relieve uremic pruritus : results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11 : 514-519, 2000.
 
13) Hsu MM, Yang CC : Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. Br J Dermatol 149 : 888-889, 2003.
 
14) Kuypers DR, Claes K, Evenepoel P, et al. : A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 19 : 1895-1901, 2004.
 
15) Gunal AI, Ozalp G, Yoldas TK, et al. : Gabapentin therapy for pruritus in haemodialysis patients : a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 19 : 3137-3139, 2004.
 
16) Wikstrom B, Gellert R, Ladefoged SD, et al. : K-opioid system in uremic pruritus : Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 16 : 3742-3747, 2005.
 
17) Nakao K, Mochizuki H : Nalfurafine hydrochloride : a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today 45 : 323-329, 2009.
PubMed
18) Kumagai H, Ebata T, Takamori K, et al. : Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients : a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 25 : 1251-1257, 2009.
PubMed
19) 中尾薫, 長谷部光, 吉川悟, 他 : オピオイドκ受容体作動薬ナルフラフィン塩酸塩の薬理作用 日神精薬理誌 30 : 185-191, 2010.
 
20) 中尾薫, 安藤晃裕, 平形美樹人, 他 : 新規経口そう痒改善薬ナルフラフィン塩酸塩 (レミッチ(R) 2.5μg) の特徴および臨床試験成績. 日薬理誌 135 : 205-214, 2010.
 
21) 山田秀和, 野田剛弘, 松倉正治, 他 : VAS法 (Visual Analogue Scale) を用いた痒みの評価法について. 皮膚 38 (増18) : 71-77, 1996.
 
22) Cho YL, Liu HN, Huang TP, et al. : Uremic pruritus : roles of parathyroid hormone and substance P. J Am Acad Dermatol 36 : 538-543 : 1997.
PubMed
23) Chou FF, Ho JC, Huang SC, et al. : A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll-Surg 190 : 65-70, 2000.
 
24) Momose A, Kudo S, Sato M, et al. : Calcium ions are abnormally distributed in the skin of haemodialysis patients with uremic pruritus. Nephrol Dial Transplant 19 : 2061-2066, 2004.
 
25) Hiroshige K, Kabashima N, Takasugi M, et al. : Optimal dialysis improves uremic pruritus. Am J Kidney Dis 25 : 413-419, 1995.
PubMed
P.133 掲載の参考文献
1) 熊谷裕生, 丸山資郎, 江畑俊哉, 他 : IV 透析治療に於ける新しい薬物 (2) 透析患者のかゆみに対するκ-アゴニスト. 臨牀透析 22 : 763-772, 2006.
 
2) 田口修之, 服部瑛, 鏑木豊, 他 : 透析患者と皮膚病変について. 臨牀透析 2 : 741-744, 1986.
 
3) 大森健太郎, 青池郁夫, 青柳春樹, 他 : 透析皮膚そう痒症の実態-新潟県内41施設2474名の調査報告-. 透析会誌 34 : 1469-1477, 2001.
 
4) 段野貴一郎 : 透析の痒み治療の最前線Visual Dermatology 3 : 526-533, 2004.
 
5) 佐藤伸一 : 痒みのメカニズムの考え方. 皮膚臨床 51 : 1209-1216, 2009.
 

書評

最近チェックした商品履歴

Loading...